drugset / Trial / NCT01054430
To Assess the Safety of Avanafil in Healthy and Hepatically Impaired Male Subjects.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to assess the single dose pharmacokinetics of avanafil in subjects with hepatic impairment and in healthy control subjects.
Timeline
- Start
- 2010-01
- Primary completion
- 2010-02
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avanafil | Small molecule | 200 mg | — |